QIAGEN OmicSoft and Biomedical Knowledge Base

Exploring bevacizumab response in low-grade glioma

83 views
August 31, 2022
See how Dr, Nilson from QIAGEN Digital Insights navigates an interesting intersection of the tumor microenvironment, mutation status, and gene expression to identify plausible activators affecting bevacizumab targets in low-grade glioma.

In this webinar participants will learn about
  • The tools used to identify key genes in LGG
  • How we choose specific gene alterations
  • The intersection between immune response tumor mutations
  • How we identify other key genes of interest 
  • How we build a network tying all these elements together

Related videos

QIAGEN OmicSoft and Biomedical Knowledge Base

Checkpoint inhibitors investigation in context of biomarkers, drug targets and pathways using...

45 views September 15, 2022

This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to...

QIAGEN IPA

Systems analysis of cancer cell lines for drug target discovery

137 views April 25, 2022

Cancer cell line models have been a cornerstone of cancer research for...

QIAGEN OmicSoft and Biomedical Knowledge Base

Inflammatory Bowel Disease: Drug Target and Biomarker Investigation using QIAGEN OmicSoft

140 views June 01, 2022

In this 90-minute training using Inflammatory Bowel Disease (IBD) public data...

QIAGEN OmicSoft and Biomedical Knowledge Base

Drug Target and Biomarker Investigation using OmicSoft OncoLand

208 views February 01, 2022

In this 90-minute training, attendees will learn how to use basic expression...